Compare Medpace Holdings Inc (MEDP) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Direxion Daily FTSE China Bull 3x Shares trades at $25.27 (market cap $560.32M). The key difference: Medpace Holdings Inc is far larger — about 30× Direxion Daily FTSE China Bull 3x Shares's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Direxion Daily FTSE China Bull 3x Shares for 25 Days on average.
| MEDP | YINN | |
|---|---|---|
Market Cap | $16.82B | $560.32M |
Volume | 223,093 | 1,009,521 |
Sector | Health | Leveraged / Inverse |
52-Week High | $630.19 | $52.69 |
52-Week Low | $393.42 | $21.45 |
Typical Hold Time | 14 Days | 25 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
YINN trades at $23.63, up 0.3% with a bearish technical outlook showing 17 sell signals versus 2 buy signals. Moving averages indicate strong bearish momentum while oscillators remain neutral. The stock faces resistance at $24 with support at $23. Recent news highlights China's economic policies affecting Asian markets, though YINN's specific fundamentals show limited available data.
The bearish technical setup and lack of clear fundamental metrics create uncertainty. Investment opportunity depends on broader market trends and China's economic developments, while risks include technical breakdown below support and regional economic volatility. Further fundamental disclosure is needed for comprehensive analysis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
